The generic labeling rule that had been drafted by the US FDA may not wind up implemented in its current form under a Scott Gottlieb-run agency, but the issue likely will not disappear.
Gottlieb opposes the proposed rule that would allow generic firms to change their labels without prior authorization. But in response...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?